Market Place
Sourcing Support
Nouscom Completes Enrollment of NOUS-209 in dMMR/MSI CRC
19 Nov 2024 //
GLOBENEWSWIRE
Nouscom`s NOUS-209 Shows Potent Immune Responses in Lynch Syndrome
05 Nov 2024 //
GLOBENEWSWIRE
Nouscom To Present NOUS-209 Data In Lynch Syndrome At SITC
04 Oct 2024 //
GLOBENEWSWIRE
Nouscom Appoints New CFO And SVP Of Technical Development
17 Jul 2024 //
GLOBENEWSWIRE
Nouscom Appoints Neil Gallagher As Independent Advisor, R&D Chair
14 May 2024 //
GLOBENEWSWIRE
Angelini Ventures Series C financing round for Nouscom
21 Mar 2024 //
GLOBENEWSWIRE
Swiss cancer vaccine biotech Nouscom raises $72M Series C for PhII trials
15 Nov 2023 //
ENDPTS
Nouscom™s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential
31 Oct 2023 //
GLOBENEWSWIRE
Nouscom reaches clinical ph II using ProBioGen’s AGE1.CR.pIX production platform
05 May 2023 //
INDIANPHARMAPOST
Nouscom Announces AACR 2023 Presentation of Phase 1b Data of NOUS-PEV
15 Mar 2023 //
GLOBENEWSWIRE
Nouscom Announces Agreement with MSD to Evaluate NOUS-209 with KEYTRUDA
05 Jan 2023 //
PR NEWSWIRE
Nouscom Announces First Patient Dosed in Phase 2 Randomized Trial with NOUS-209
15 Nov 2022 //
PRNEWSWIRE
Nouscom announces leading publication revealing an immune mechanism of action
11 Aug 2022 //
PRNEWSWIRE
Nouscom Announces Positive Full PI Data of NOUS-209 in dMMR/MSI-H Solid Tumors
06 Jun 2022 //
PRNEWSWIRE
Nouscom to Present Full Phase 1 Data of NOUS-209 in dMMR/MSI-H Solid Tumors
26 May 2022 //
PRNEWSWIRE
Nouscom Announces New Translational Phase 1 Data of NOUS-209 at AACR 2022
11 Apr 2022 //
PRNEWSWIRE
Nouscom receives approval to begin Phase 1b trials of NOUS-PEV
11 Mar 2021 //
PRNEWSWIRE
Nouscom highlights cutting-edge science that led to the design of NOUS-209
22 Jul 2020 //
PRESS RELEASE
Nouscom interim CEO becomes full-time as Amal exec becomes CMO
27 Feb 2020 //
FIERCE BIOTECH
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.